Literature DB >> 3498628

Prostatic epidermal growth factor receptors and their regulation by androgens.

A M Traish1, H H Wotiz.   

Abstract

Prostatic membranes contain high affinity [dissociation constant (KD) = 1.16 nM], saturable binding sites for [125I]iodo-epidermal growth factor (EGF). The binding of [125I]iodo-EGF is specific since it is displaced by excess EGF but not by insulin, fibroblast growth factor, platelet-derived growth factor, or multiplication-stimulating activity. Affinity labeling with [125I]iodo-EGF and subsequent cross-linking with disuccinimidyl suberate demonstrated the specific binding of [125I]iodo-EGF to a macromolecule with a mol wt of 170,000. Castration of mature rats resulted in a 3- to 6-fold increase in [125I]iodo-EGF binding, while treatment of 7-day castrated rats with 5 alpha-dihydrotestosterone decreased the number of binding sites. Administration of estrogen or progesterone produced a slight decrease in EGF binding sites but not nearly to the extent observed with 5 alpha-dihydrotestosterone, suggesting that the observed effect is androgen specific. These results demonstrate that rat prostate contains specific binding sites for EGF and that their level is modulated by androgens.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498628     DOI: 10.1210/endo-121-4-1461

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  20 in total

Review 1.  Morphologic and regulatory aspects of prostatic function.

Authors:  G Aumüller
Journal:  Anat Embryol (Berl)       Date:  1989

Review 2.  Prostate gland: structure, functions and regulation.

Authors:  V L Kumar; P K Majumder
Journal:  Int Urol Nephrol       Date:  1995       Impact factor: 2.370

Review 3.  Fibroblasts are critical determinants in prostatic cancer growth and dissemination.

Authors:  L W Chung
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

Review 4.  Growth factors as mediators of androgen action during the development of the male urogenital tract.

Authors:  G R Cunha; B Foster; A Thomson; Y Sugimura; N Tanji; M Tsuji; N Terada; P W Finch; A A Donjacour
Journal:  World J Urol       Date:  1995       Impact factor: 4.226

5.  The effect of sustained and local administration of epidermal growth factor on improving bilateral testicular tissue after torsion.

Authors:  S Uguralp; A Bay Karabulut; B Mizrak; F Kaymaz; Aysel Kiziltay; N Hasirci
Journal:  Urol Res       Date:  2004-08-28

6.  Monitoring therapeutic response of human ovarian cancer to 17-DMAG by noninvasive PET imaging with (64)Cu-DOTA-trastuzumab.

Authors:  Gang Niu; Zibo Li; Qizhen Cao; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-14       Impact factor: 9.236

Review 7.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

Review 8.  Nutrition and renal cell cancer.

Authors:  A Wolk; P Lindblad; H O Adami
Journal:  Cancer Causes Control       Date:  1996-01       Impact factor: 2.506

9.  Androgen regulation of epidermal growth factor receptor binding activity during fetal rabbit lung development.

Authors:  J M Klein; H C Nielsen
Journal:  J Clin Invest       Date:  1993-02       Impact factor: 14.808

10.  Regional distribution of epidermal growth factor, testosterone and dihydrotestosterone in benign prostatic hyperplasia tissue.

Authors:  F Sciarra; S Monti; M V Adamo; E Palma; V Toscano; G d'Eramo; F di Silverio
Journal:  Urol Res       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.